087010.KQ Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (24 Apr 2024 @ 02:30):

Stats
Today's Volume	483 672
Average Volume	696 144
Market Cap	543.88B
EPS	KRW0 ( 2024-03-15 )
Next earnings date	( KRW0 ) 2024-05-12
Last Dividend	KRW0 ( N/A )
Next Dividend	KRW0 ( N/A )
P/E	0
ATR14	KRW88.82 (0.32%)

Volume Correlation

Long: -0.11 (neutral)

Short: -0.21 (neutral)

Signal:(48.559) Neutral

Peptron, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Peptron, Inc. Correlation - Currency/Commodity

0.74
( moderate )

0.65
( weak )

0.10
( neutral )

0.74
( moderate )

-0.14
( neutral )

-0.26
( neutral )

Peptron, Inc. Financials

Annual	2023
Revenue:	KRW3.34B
Gross Profit:	KRW-1.75B (-52.48 %)
EPS:	KRW-773.61

Q4	2023
Revenue:	KRW799.67M
Gross Profit:	KRW-319.41M (-39.94 %)
EPS:	KRW-158.70

Q3	2023
Revenue:	KRW683.47M
Gross Profit:	KRW-467.04M (-68.33 %)
EPS:	KRW-201.39

Q2	2023
Revenue:	KRW695.35M
Gross Profit:	KRW-421.63M (-60.64 %)
EPS:	KRW-218.97

Financial Reports:

No articles found.

Peptron, Inc.

Peptron, Inc. engages in the development of peptide-based medicines to treat chronic diseases. The company's technologies include long acting; and SmartDepot, an ultrasonic spray drying technology for the preparation of sustained release injectable microsphere formulation of drug. Its research and development products include Luphere Depot for prostate cancer, endometriosis, uterine fibroids, and puberty; SR-Octreotide (PT201) for the treatment of acromegaly; SR-Exenatide (PT302) to treat type 2 diabetes; and SR-Exenatide (PT320) for Parkinson's and Alzheimer's disease. Peptron, Inc. was founded in 1997 and is headquartered in Daejeon, South Korea.